Beneficial effects of evogliptin, a novel dipeptidyl peptidase 4 inhibitor, on adiposity with increased Ppargc1a in white adipose tissue in obese mice

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Chae, Yu Na ^a   Kim, Tae Hyoung ^a   Kim, Mi Kyung ^a   Shin, Chang Yell ^a   Jung, Il Hoon ^a   Sohn, Yong Sung ^a   Son, Moon Ho ^a  

^a Dong A ST Co Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EVOGLIPTIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LINAGLIPTIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; 4-(3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL)-3-(TERT-BUTOXYMETHYL)PIPERAZIN-2-ONE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; PIPERAZINE DERIVATIVE; PPARGC1A PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL METABOLIC RATE; BODY COMPOSITION; BROWN ADIPOSE TISSUE; CALORIC INTAKE; CONTROLLED STUDY; COX4I1 GENE; DOSE RESPONSE; DRUG EFFECT; ENERGY CONSUMPTION; ENERGY EXPENDITURE; ENZYME INHIBITION; FAT MASS; GENE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; PPARGC1A GENE; SINGLE DRUG DOSE; SKELETAL MUSCLE; TREATMENT DURATION; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENETICS; METABOLISM;

ADIPOSE TISSUE, WHITE; ADIPOSITY; ANIMALS; BLOOD GLUCOSE; BODY COMPOSITION; DIET, HIGH-FAT; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; MALE; MICE; MICE, INBRED C57BL; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; PIPERAZINES; TRANSCRIPTION FACTORS; WEIGHT LOSS;

EID: 84955494565     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144064     Document Type: Article

References (60)

1. Guillet C, Masgrau A, Walrand S, Boirie Y. Impaired protein metabolism: interlinks between obesity, insulin resistance and inflammation. Obes Rev. 2012; 13 Suppl 2: 51-57. PMID: 23107259 doi: 10.1111/j.1467-789X.2012.01037.x
2. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011; 60(7): 1917-1925. PMID: 21593202 doi: 10.2337/db10-1707
3. Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother. 2012; 13(1): 81-99. PMID: 22149369 doi: 10.1517/14656566.2012.642866
4. Cahn A, Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs. 2013; 18(2): 245-258. PMID: 23725569 doi: 10.1517/14728214.2013.807796
5. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007; 298(2): 194-206. PMID: 17622601
6. Lamont BJ, Drucker DJ. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes. 2008; 57(1): 190-198. PMID: 17928394
7. Hamamoto S, Kanda Y, Shimoda M, Tatsumi F, Kohara K, Tawaramoto K, et al. Vildagliptin preserves the mass and function of pancreatic beta cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetes Obes Metab. 2013; 15(2): 153-163. PMID: 22950702 doi: 10.1111/dom.12005
8. Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-yl methyl)-3,7-dihydropurine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther. 2009; 328(2): 556-563. doi: 10.1124/jpet.108.143966
9. Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes. 2007; 56(12): 3006-3013. PMID: 17717280
10. Kern M, Klöting N, Niessen HG, Thomas L, Stiller D, Mark M, et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One. 2012; 7(6): e38744. PMID: 22761701 doi: 10.1371/journal.pone.0038744
11. Challa TD, Beaton N, Arnold M, Rudofsky G, Langhans W, Wolfrum C. Regulation of adipocyte formation by GLP-1/GLP-1R signaling. J Biol Chem. 2012; 287(9): 6421-6430. PMID: 22207759 doi: 10.1074/jbc.M111.310342
12. Vendrell J, El Bekay R, Peral B, Garcia-Fuentes E, Megia A, Macias-Gonzalez M, et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology. 2011; 152(11): 4072-4079. PMID: 21862620 doi: 10.1210/en.2011-1070
13. Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljanski J, et al. Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. Diabetes Metab Syndr Obes. 2013; 6: 171-185. PMID: 23667315 doi: 10.2147/DMSO.S41827
14. Flint A, Kapitza C, Zdravkovic M. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment. Diabetes Obes Metab. 2013; 15(10): 958-962. PMID: 23551925 doi: 10.1111/dom.12108
15. Elfers CT, Simmons JH, Roth CL. Glucagon-like peptide-1 agonist exendin-4 leads to reduction of weight and caloric intake in a rat model of hypothalamic obesity. Horm Res Paediatr. 2012; 78(1): 47-53. PMID: 22831885 doi: 10.1159/000338464
16. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A. 2003; 100(11):6825-6830. PMID: 12748388
17. Kim MK, Chae YN, Kim HD, Yang EK, Cho EJ, Choi SH, et al. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci. 2012; 90(1-2): 21-29. PMID: 22056373 doi: 10.1016/j.lfs.2011.10.007
18. Kos K, Baker AR, Jernas M, Harte AL, Clapham JC, O'Hare JP, et al. DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab. 2009; 11(4): 285-92. PMID: 19175376 doi: 10.1111/j.1463-1326.2008.00909.x
19. Rosmaninho-Salgado J, Marques AP, Estrada M, Santana M, Cortez V, Grouzmann E, et al. Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-gamma expression. Peptides. 2012; 37(1): 49-54. PMID: 22819773 doi: 10.1016/j.peptides.2012.06.014
20. Kirino Y, Kamimoto T, Sato Y, Kawazoe K, Minakuchi K, Nakahori Y. Increased plasma dipeptidyl peptidase IV (DPP IV) activity and decreased DPP IV activity of visceral but not subcutaneous adipose tissue in impaired glucose tolerance rats induced by high-fat or high-sucrose diet. Biol Pharm Bull. 2009; 32(3): 463-467. PMID: 19252296
21. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K. Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats. Am J Physiol Endocrinol Metab. 2011; 300(2): E372-E379. PMID: 21139073 doi: 10.1152/ajpendo.00319.2010
22. Fukuda-Tsuru S, Kakimoto T, Utsumi H, Kiuchi S, Ishii S. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. Eur J Pharmacol. 2014; 723: 207-215. PMID: 24309217 doi: 10.1016/j.ejphar.2013.11.030
23. Cho JM, Jang HW, Cheon H, Jeong YT, Kim DH, Lim YM, et al. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing beta-cell replication and neogenesis. Diabetes Res Clin Pract. 2011; 91: 72-79. PMID: 21093089 doi: 10.1016/j.diabres.2010.10.012
24. Kim HJ, Kwak WY, Min JP, Lee JY, Yoon TH, Kim HD, et al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2011; 21: 3809-3812. PMID: 21570283 doi: 10.1016/j.bmcl.2011.04.029
25. Mu J, Petrov A, Eiermann GJ, Woods J, Zhou YP, Li Z, et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol. 2009; 623:148-154. PMID: 19765579 doi: 10.1016/j.ejphar.2009.09.027
26. Wu YJ, Guo X, Li CJ, Li DQ, Zhang J, Yang Y, et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism. 2015; 64(2): 226-235. PMID: 25195070 doi: 10.1016/j.metabol.2014.08. 006
27. Vyas AK, Aerni-Flessner LB, Payne MA, Kovacs A, Jay PY, Hruz PW. Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated Cardiomyopathy. Cardiovasc Endocrinol. 2012; 1(14): 74-82. PMID: 23795310
28. Cannavino J, Brocca L, Sandri M, Bottinelli R, Pellegrino MA. PGC1-α over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J Physiol. 2014; 592(Pt 20): 4575-4589. PMID: 25128574 doi: 10.1113/jphysiol.2014.275545
29. Yo K, Yu YM, Zhao G, Bonab AA, Aikawa N, Tompkins RG, et al. Brown adipose tissue and its modulation by a mitochondria-targeted peptide in rat burn injury-induced hypermetabolism. Am J Physiol Endocrinol Metab. 2013; 304(4): E331-E341. PMID: 23169784 doi: 10.1152/ajpendo.00098.2012
30. Bartelt A, Heeren J. Adipose tissue browning and metabolic health. Nat Rev Endocrinol. 2014; 10(1): 24-36. PMID: 24146030 doi: 10.1038/nrendo.2013.204
31. Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A. Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques. 2004; 37(1): 112-114, 116, 118-119. PMID: 15283208
32. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a doubleblind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006; 28(1):55-72. PMID: 16490580
33. Even PC, Nadkarni NA. Indirect calorimetry in laboratory mice and rats: principles, practical considerations, interpretation and perspectives. Am J Physiol Regul Integr Comp Physiol. 2012; 303(5): R459-R476. PMID: 22718809 doi: 10.1152/ajpregu.00137.2012
34. Wendel AA, Purushotham A, Liu LF, Belury MA. Conjugated linoleic acid induces uncoupling protein 1 in white adipose tissue of ob/ob mice. Lipids. 2009; 44(11): 975-982. PMID: 19779754 doi: 10.1007/s11745-009-3348-9
35. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A. 2003; 100(14): 8466-8471. PMID: 12832613
36. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature. 2002; 418(6899): 797-801. PMID: 12181572
37. Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ. 2006; 30(4): 145-151. PMID: 17108241
38. Bogacka I, Xie H, Bray GA, Smith SR. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes. 2005; 54(5): 1392-1399. PMID: 15855325
39. Talsania T, Anini Y, Sinus S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology. 2005; 146(9): 3748-3756. PMID: 15932924
40. Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther. 2013; 35(3): 273-285.e7. PMID: 23433601 doi: 10.1016/j.clinthera.2013.01.010
41. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995; 269(5223): 546-549. PMID: 7624778
42. Ceddia RB. Direct metabolic regulation in skeletal muscle and fat tissue by leptin: implications for glucose and fatty acids homeostasis. Int J Obes (Lond). 2005; 29(10):1175-1183. PMID: 16030519
43. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond). 2006; 30(9): 1332-1340. PMID: 16534527
44. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology. 2004; 127(2): 546-558.PMID: 15300587
45. Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012; 97(2): 258-266. PMID: 22446097 doi: 10.1016/j.diabres.2012.02.016
46. Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000; 24(3): 288-298. PMID: 10757621
47. Pannacciulli N, Bunt JC, Koska J, Bogardus C, Krakoff J. Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr. 2006; 84(3): 556-560. PMID: 16960169
48. Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA. Alterations in energy balance following exenatide administration. Appl Physiol Nutr Metab. 2012; 37: 893-899. PMID: 22735035 doi: 10.1139/h2012-068
49. Goldsmith F, Keenan MJ, Raggio AM, Ye X, Hao Z, Durham H, et al. Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 Receptor. PLoS One. 2015; 10(5): e0126177. PMID: 25938560
50. Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2009; 94(3):846-852. PMID: 19088168 doi: 10.1210/jc.2008-1400
51. Dobrian AD, Ma Q, Lindsay JW, Leone KA, Ma K, Coben J, et al. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab. 2011; 300(2):E410-E421. PMID: 21081706 doi: 10.1152/ajpendo.00463.2010
52. Souza-Mello V, Gregório BM, Cardoso-de-Lemos FS, de Carvalho L, Aguila MB, Mandarim-de- Lacerda CA. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond). 2010; 119(6):239-250. PMID: 20415664 doi: 10.1042/CS20100061
53. Sawada T, Miyoshi H, Shimada K, Suzuki A, Okamatsu-Ogura Y, Perfield JW 2nd, et al. Perilipin overexpression in white adipose tissue induces a brown fat-like phenotype. PLoS One. 2010; 5(11): e14006. PMID: 21103377 doi: 10.1371/journal.pone.0014006
54. Abernathy RP, Black DR. Healthy body weights: an alternative perspective. Am J Clin Nutr. 1996; 63(3 Suppl):448S-451S. PMID: 8615340
55. Gaidhu MP, Anthony NM, Patel P, Hawke TJ, Ceddia RB. Dysregulation of lipolysis and lipid metabolism in visceral and subcutaneous adipocytes by high-fat diet: role of ATGL, HSL, and AMPK. Am J Physiol Cell Physiol. 2010; 298(4):C961-971. PMID: 20107043 doi: 10.1152/ajpcell.00547.2009
56. Gaidhu MP, Fediuc S, Anthony NM, So M, Mirpourian M, Perry RL, et al. Prolonged AICAR-induced AMP-kinase activation promotes energy dissipation in white adipocytes: novel mechanisms integrating HSL and ATGL. J Lipid Res. 2009; 50(4):704-715. PMID: 19050316 doi: 10.1194/jlr.M800480-JLR200
57. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006; 116(3): 615-622. PMID: 16511594
58. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab. 2007; 92(3): 1023-1033. PMID: 17164304
59. Verhoef SPM, van Dijk P, Westerterp KR. Relative shrinkage of adipocytes by paraffin in proportion to plastic embedding in human adipose tissue before and after weight loss. Obes Res Clin Pract. 2013; 7: e8-13. PMID: 24331678 doi: 10.1016/j.orcp.2012.03.001
60. Son MH, Kim HD, Chae YN, Kim MK, Shin CY, Ahn GJ, et al. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. Int J Obes (Lond). 2010; 34(3): 547-556. PMID: 20029379 doi: 10.1038/ijo.2009.253